Kangyun Internet Secures Tens of Millions in Angel Funding for Revolutionary Instrument-Free In Vitro Diagnostics Platform

On the afternoon of November 4, Wu Fan, CEO of Kangyun Interconnect, disclosed to VCBeat (WeChat ID: vcbeat) that the company had recently secured tens of millions of yuan in angel-round financing. The investor, Qingqing Mango Asset Investment Management Co., Ltd., is a state-controlled professional investment firm.

Following this round of financing, Kangyun Hulian’s valuation reached hundreds of millions of yuan.

This round marks the third financing secured by Kangyun Interconnect. What aspects of Kangyun Interconnect attracted investors? In response, Wu Fan offered only a concise explanation: “We possess core technological capabilities and R&D strength, with unique products and outstanding resilience to economic cycles.”

As previously reported by VCBeat (WeChat ID: vcbeat), Kangyun Interconnect, a company founded in March 2016, is primarily engaged in in vitro diagnostics-related businesses, aiming to provide users with “Internet+” solutions for health screening, basic diagnosis, and smart healthcare. (See details:Kangyun Interconnect: A New “Internet+” Model for In Vitro Diagnostics）

Product Images of Kangyun Hulian

Kangyun Hulian’s inaugural product is an in vitro diagnostic chip. When a test sample comes into contact with the sensors on the chip, a chemical reaction occurs. Users can take a photo of the chip containing the test sample and upload it to the server, enabling real-time display of the test results on their mobile devices. The system supports a range of tests, including vital signs monitoring, nucleic acid testing, routine biochemical assays, routine immunological assays, protein assays, and routine urinalysis.

Meanwhile, Kangyun Interconnect has also launched a WeChat-based testing platform. After users upload photos of the test chips to the Kangyun Interconnect official WeChat account, the account will automatically reply with the test results.

Currently, the in vitro diagnostics (IVD) market is dominated by the development of testing instruments. Kangyun Interconnect has chosen not to compete in this segment but has instead pioneered an alternative approach characterized by “instrument-free” and “app-free” solutions. Without the need for dedicated testing devices or downloading numerous mobile applications, users can obtain IVD results as long as they have internet access.

According to reporters, the “Chemical Analysis Cloud Detection System” launched by Kangyun Interconnect is based on biosensor technology, the Internet of Things (IoT), and cloud computing, and features an independent intellectual property rights system. Specifically, it employs a hardware-free and app-free approach through smart consumables, plugins, and cloud computing to enable mobile-side test data collection and mining, allowing users to obtain test results in a timely manner.

This system is not only applicable to the field of medical testing, but also boasts broad application prospects. It has already been deployed in collaboration with central state-owned enterprises in areas such as food safety and environmental water quality safety, and will play a significant role in the public safety emergency response industry.

Wu Fan informed us that following this round of financing, Kangyun Interconnect will comprehensively accelerate application development and market promotion in the broader healthcare sector. This includes providing “healthcare + internet” solutions for routine urinalysis, routine biochemistry, and immunoassays in the areas of primary care, telemedicine, and chronic disease management. The company will also expedite its collaboration with Datang Telecom’s Mobile Internet Southern Base in the field of public safety.

Of course, a more detailed development plan has not yet been finalized and remains to be determined. VCBeat (WeChat ID: vcbeat) will continue to monitor the situation closely.